{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:16:01Z","timestamp":1793304961368,"version":"4.5.0"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mBio"],"published-print":{"date-parts":[[2023,12,19]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The use of convalescent plasma (CP) for hospitalized patients with SARS-CoV-2 infection might be a useful option in certain settings. Soon after the outbreak of COVID-19, the National Ministry of Health of Argentina recommended the use of CP transfusion for hospitalized patients with COVID-19 disease. Between 1 June and 3 October 2020, 480 patients, excluding those on invasive mechanical ventilation (IMV), received at least one CP infusion in the province of Santa Fe. We aimed to find factors associated with mortality among this cohort of patients. The median age was 60 years (interquartile range: 49\u201369 years) and 320 (66.7%) were males. Most of these patients (93.75%) received a single CP infusion, 82.1% and 95.6% before day 4 and day 7 of hospitalization, respectively. Anti-SARS-CoV-2 titers were determined in the CP units administered using Elecsys Anti-SARS-CoV-2 S assay. At 28 days of follow-up, 250 patients were discharged (52.1%), 131 (27.3%) remained hospitalized without and 16 (3.3%) with oxygen requirement, 27 (5.6%) were on IMV, and 56 (11.7%) had died. In the multivariate logistic regression analysis, the factors significantly associated with 28-day mortality were (i) requirement of IMV, (ii) the administration of CP after the third day of hospitalization, (iii) age, and (iv) number of comorbidities. The qualitative and quantitative analyses of antibodies against SARS-CoV-2 in the infused CP were not associated with mortality. Our findings may imply a seemingly favorable effect of CP administration among patients with severe COVID-19 disease when infused sooner after hospitalization.<\/jats:p>\n          <jats:sec>\n            <jats:title>IMPORTANCE<\/jats:title>\n            <jats:p>The use of convalescent plasma (CP) could be an option for patients with severe COVID-19, especially in poor-resource countries where direct antiviral drugs are not commercially available. Currently, the U.S. Food and Drug Administration limits the CP administration for outpatients and inpatients with COVID-19 who are immunocompromised and only if high levels of anti-SARS-CoV-2 antibodies are confirmed in the CP unit. Although most of the randomized clinical trials failed to show a clear-cut benefit of CP in hospitalized patients with severe COVID-19, other studies have shown that if given early in the course of the disease, it might be a useful therapeutic option. In this retrospective study, we demonstrated that early treatment (within 3 days of hospitalization) was significantly associated with reduced 28-day mortality compared with those patients treated beyond day 3. The results from our study add up to the scientific evidence on the use of CP as a relatively safe, cheap, and possibly effective therapy in certain patients suffering from severe SARS-CoV-2 infection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/mbio.01777-23","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T14:03:01Z","timestamp":1699452181000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma"],"prefix":"10.1128","volume":"14","author":[{"given":"Armando M.","family":"Perichon","sequence":"first","affiliation":[{"name":"Centro \u00danico de Donaci\u00f3n, Ablaci\u00f3n e Implante de \u00d3rganos, Ministerio de Salud, Rosario, Santa Fe, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Acosta","sequence":"additional","affiliation":[{"name":"Centro Regional de Hemoterapia Sur, Ministerio de Salud, Rosario, Santa Fe, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Di Tulio","sequence":"additional","affiliation":[{"name":"Centro Regional de Hemoterapia Sur, Ministerio de Salud, Rosario, Santa Fe, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Munuce","sequence":"additional","affiliation":[{"name":"Laboratorio de Medicina Reproductiva\u2013\u00c1rea Bioqu\u00edmica Cl\u00ednica-Facultad de Ciencias Bioqu\u00edmicas y Farmac\u00e9uticas, Universidad Nacional de Rosario, Rosario, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Pezzotto","sequence":"additional","affiliation":[{"name":"Instituto de Inmunolog\u00eda Cl\u00ednica y Experimental de Rosario, Universidad Nacional de Rosario-CONICET, Rosario, Argentina"},{"name":"Consejo de Investigaciones, Universidad Nacional de Rosario, Rosario, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Bottasso","sequence":"additional","affiliation":[{"name":"Instituto de Inmunolog\u00eda Cl\u00ednica y Experimental de Rosario, Universidad Nacional de Rosario-CONICET, Rosario, Argentina"},{"name":"Consejo de Investigaciones, Universidad Nacional de Rosario, Rosario, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8472-7965","authenticated-orcid":true,"given":"Esteban C.","family":"Nannini","sequence":"additional","affiliation":[{"name":"Instituto de Inmunolog\u00eda Cl\u00ednica y Experimental de Rosario, Universidad Nacional de Rosario-CONICET, Rosario, Argentina"},{"name":"Servicio de Infectolog\u00eda, Sanatorio Brit\u00e1nico, Rosario, Santa Fe, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(79)92335-3"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(84)90299-x"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004168117"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031304"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033700"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119657"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031893"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.11.23284347"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.09.21252736"},{"key":"e_1_3_3_12_2","unstructured":"NIH. 2023. COVID-19 Treatment guidelines: Clinical spectrum of SARS-CoV-2 infection. Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/overview\/clinical-spectrum"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848582"},{"key":"e_1_3_3_15_2","unstructured":"Villa C. 2021. FDA. Clinical memorandum: COVID-19 convalescent plasma. Available from: https:\/\/www.fda.gov\/media\/155159\/download"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1783"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.02.001"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.10.008"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab834"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00200-21"},{"key":"e_1_3_3_21_2","unstructured":"IDSA. 2023. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Available from: https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","unstructured":"Group RC. 2022. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised controlled open-label platform trial. lancet (London England) 399:665\u2013676.","DOI":"10.1016\/S0140-6736(22)00163-5"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271036"}],"container-title":["mBio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mbio.01777-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mbio.01777-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T20:08:15Z","timestamp":1703275695000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/mbio.01777-23"}},"subtitle":[],"editor":[{"given":"Arturo","family":"Casadevall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12,19]]}},"alternative-id":["10.1128\/mbio.01777-23"],"URL":"https:\/\/doi.org\/10.1128\/mbio.01777-23","relation":{},"ISSN":["2150-7511"],"issn-type":[{"value":"2150-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"2023-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01777-23"}}